DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Slides:

Advertisements

Similar presentations

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Advertisements

Uptake of T-MPs for DC maturation and antigen presentation.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival by Matthew Gumbleton, Raki Sudan,

Cetuximab treatment increases IFNγ receptor 1 expression.

Functions of myeloid cells.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Epithelial loss of TβRII results in increased Th17 cell development.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

Exosome-mediated inhibition of T cells is reversible.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Dox titration and kinetic analyses of CD19CAR expression upon Dox administration and discontinuation. Dox titration and kinetic analyses of CD19CAR expression.

RvD1 increased anti-inflammatory macrophages and Treg cells in the sciatic nerves of EAN rats. RvD1 increased anti-inflammatory macrophages and Treg cells.

NK Cells Fighting Cancer

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Adaptive NK cells resist immunosuppression in the tumor microenvironment. Adaptive NK cells resist immunosuppression in the tumor microenvironment. FACS-sorted.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Figure 3. Enhancement of cytokine production by CD8+ T cells at TT

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

Possible mechanisms of recognition of MHCIlow tumor cells by NSCs

CD11bhighCD27high conventional NK cells are converted into MDSCs

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

DAC treatment activates expression of immunoregulatory genes.

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Tregs preferentially regulate TH2 cytokines in skin.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

CPI-444 enhances T-cell activation in MC38 tumors.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Impact of IFNγ in B16 melanoma metastasis.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Activation status of NK cells is associated with therapeutic effects of TKIs. PBMCs from CML patients were cocultured with HLA class I–deficient K562 cells.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

MDSC population in patient peripheral blood.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

GK1 enhances the secretion of proinflammatory cytokines resulting from cognate interactions between activated DCs and T cells. GK1 enhances the secretion.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Varying the MHC-I affinity, TCR affinity or antigen dose alters the phenotype of CD8 T cells ex vivo. Varying the MHC-I affinity, TCR affinity or antigen.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Presentation transcript:

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. FVB mice were dosed according to the schema in Fig. 2A. On day 14 after tumor inoculation, a peritoneal wash was performed, and single-cell suspensions were analyzed by flow cytometry. A, representative figures of flow-cytometric analyses of tumor-associated CD4+ T cells, CD8+ T cells, CD4+Foxp3+ Tregs, NK cells, and CD11b+Gr1+ MDSCs among control- and DAC-treated mice. B, quantitation of results from A with statistical analysis. C and D, cell suspensions from the peritoneal wash were stimulated with PMA and ionomycin for 4 hours, and stimulated cells were then analyzed for expression of CD3, CD8, Nkp46, IFNγ, and TNFα by flow cytometry. C, representative results are shown for control- and DAC-treated cells. D, quantitation of results from C with statistical analysis. **, P < 0.005; ***, P < 0.0005; ****, P < 0.0001. Representative of three independent experiments. Lei Wang et al. Cancer Immunol Res 2015;3:1030-1041 ©2015 by American Association for Cancer Research